Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML.

× No keyword cloud information.

11 in total

1. EVI1-rearranged acute myeloid leukemias are characterized by distinct molecular alterations.

Authors: Vincent-Philippe Lavallée; Patrick Gendron; Sébastien Lemieux; Giovanni D'Angelo; Josée Hébert; Guy Sauvageau
Journal: Blood Date: 2014-10-20 Impact factor: 22.113

2. Screening of mutations in the additional sex combs like 1, transcriptional regulator, tumor protein p53, and KRAS proto-oncogene, GTPase/NRAS proto-oncogene, GTPase genes of patients with myelodysplastic syndrome.

Authors: Carolina Leite; Lucas Delmonico; Gilda Alves; Romario José Gomes; Mariana Rodrigues Martino; Aline Rodrigues da Silva; Aline Dos Santos Moreira; Maria Christina Maioli; Luciano Rios Scherrer; Elenice Ferreira Bastos; Roberto Irineu; Maria Helena Ornellas
Journal: Biomed Rep Date: 2017-08-09

Review 3. [Myelodysplastic syndromes. Epidemiology, molecular and morphological characteristics and risk stratification].

Authors: A H Schmitt-Graeff; M J Müller; P Fisch
Journal: Pathologe Date: 2013-02 Impact factor: 1.011

4. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study.

Authors: Heesun J Rogers; James W Vardiman; John Anastasi; Gordana Raca; Natasha M Savage; Athena M Cherry; Daniel Arber; Erika Moore; Jennifer J D Morrissette; Adam Bagg; Yen-Chun Liu; Susan Mathew; Attilio Orazi; Pei Lin; Sa A Wang; Carlos E Bueso-Ramos; Kathryn Foucar; Robert P Hasserjian; Ramon V Tiu; Matthew Karafa; Eric D Hsi
Journal: Haematologica Date: 2014-01-24 Impact factor: 9.941

5. Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors.

Authors: Wei Wang; Jorge E Cortes; Pei Lin; Michael W Beaty; Di Ai; Hesham M Amin; Timothy J McDonnell; Chi Young Ok; Hagop M Kantarjian; L Jeffrey Medeiros; Shimin Hu
Journal: Blood Date: 2015-08-04 Impact factor: 22.113

Review 6. The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes.

Authors: Azra Raza; Naomi Galili
Journal: Nat Rev Cancer Date: 2012-12 Impact factor: 60.716

7. Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways.

Authors: Stefan Gröschel; Mathijs A Sanders; Remco Hoogenboezem; Annelieke Zeilemaker; Marije Havermans; Claudia Erpelinck; Eric M J Bindels; H Berna Beverloo; Hartmut Döhner; Bob Löwenberg; Konstanze Döhner; Ruud Delwel; Peter J M Valk
Journal: Blood Date: 2014-11-07 Impact factor: 22.113

Review 8. EVI1 dysregulation: impact on biology and therapy of myeloid malignancies.

Authors: Christine Birdwell; Warren Fiskus; Tapan M Kadia; Courtney D DiNardo; Christopher P Mill; Kapil N Bhalla
Journal: Blood Cancer J Date: 2021-03-22 Impact factor: 11.037

9. EVI1 and GATA2 misexpression induced by inv(3)(q21q26) contribute to megakaryocyte-lineage skewing and leukemogenesis.

Authors: Ayaka Yamaoka; Mikiko Suzuki; Saori Katayama; Daiki Orihara; James Douglas Engel; Masayuki Yamamoto
Journal: Blood Adv Date: 2020-04-28

10. Gene expression patterns of hemizygous and heterozygous KIT mutations suggest distinct oncogenic pathways: a study in NIH3T3 cell lines and GIST samples.

Authors: Jean-Baptiste Bachet; Séverine Tabone-Eglinger; Sophie Dessaux; Anthony Besse; Sabrina Brahimi-Adouane; Jean-François Emile; Jean-Yves Blay; Laurent Alberti
Journal: PLoS One Date: 2013-04-12 Impact factor: 3.240